Welcome

The Inter-American Society of Hypertension (IASH) is a non-profit organization devoted to the understanding, prevention, and control of hypertension and vascular diseases with emphasis on bridging basic, translational, and clinical research across the Americas.

Membership is extended to scientists, physicians, and health care providers from 20 different countries in the Americas, Europe, Australia, and Asia. Anyone interested in the field of hypertension, cardiometabolic risk factors, and cardiovascular diseases is welcome to join the society.

Sign up to receive our newsletter:

SIGN UP

2017 AHA COUNCIL ON HYPERTENSION, AHA COUNCIL ON KIDNEY IN CARDIOVASCULAR DISEASE, AND AMERICAN SOCIETY OF HYPERTENSION JOINT SCIENTIFIC SESSIONS 

September 14-17, 2017

 IASH continues its commitment to facilitate attendance of New Investigators from Latin America at the hypertension-related conferences in the USA. During the 2017 AHA Council on Hypertension, AHA Council on Kidney in Cardiovascular Disease, and American Society of Hypertension Joint Scientific Sessions held in San Francisco, CA,  IASH presented two new investigators with awards. The top 2 scored presenters were:

  • Dr. Barrera-Chimal (Myeloid Mineralocorticoid Receptor Controls Inflammatory and Fibrotic Responses After Renal Ischemic Injury via Macrophage Interleukin-4 Receptor; Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico, First place)  and
  • Dr. Duarte (Baroreflex Hypofunction is Due to Increased Arterial Stiffness in Chronic Hypertension; Hospital de Clínicas, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina, Second Place). Although in the second place Dr. Duarte received travel award of $US 1, 000 from IASH because Dr. Barrera-Chimal had already been selected to receive a travel award from the Council on Kidney in Cardiovascular Disease.

The IASH was very pleased to support the career advancement of these young talented investigators! Visit our photo album on Facebook (https://www.facebook.com/IASHonline) to check more pictures of the IASH activities during this scientific meeting.

THE SPRINT TRIAL: A RANDOMIZED TRIAL OF INTENSIVE VERSUS STANDARD BLOOD PRESSURE CONTROL

November 26, 2015

The SPRINT trial compared less-tight control with tight control of hypertension in patients with increased cardiovascular risk but without diabetes. The study included 4678 patients assigned to the intensive treatment of systolic blood pressure (target, <120 mm Hg) and 4683 patients assigned to standard treatment (target, <140 mm Hg). The authors concluded that among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group (NEJM, November 26, 2015).

Download PowerPoint »

DUAL RENIN ANGIOTENSIN SYSTEM BLOCKADE

July 10, 2015

Two studies evaluated the effect of lisinopril combined with telmisartan in early and late stage polycystic kidney disease. In late-stage polycystic kidney disease the rates of decline in the estimated GFR, urinary albumin excretion, and adverse events, including hyperkalemia and acute kidney injury, did not also differ significantly between two groups. Similar conclusions were derived from another published study in which lisinopril and telmisartan were employed in early stage of autosomal dominant polycystic kidney disease.

(Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; the HALT-PKD Trial Investigators. Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2014 Dec 11;371(24):2267-2276;

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; the HALT-PKD Trial Investigators. Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2014 Dec 11;371(24):2255-2266)